LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Search

Twist Bioscience Corp

Chiusa

SettoreSettore sanitario

48.29 0.73

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

46.46

Massimo

49

Metriche Chiave

By Trading Economics

Entrata

-3.4M

-31M

Vendite

4.7M

104M

Margine di Profitto

-29.419

Dipendenti

979

EBITDA

-3.2M

-24M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+8.13% upside

Dividendi

By Dow Jones

Utili prossimi

4 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

409M

3B

Apertura precedente

47.56

Chiusura precedente

48.29

Notizie sul Sentiment di mercato

By Acuity

50%

50%

161 / 351 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Twist Bioscience Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 feb 2026, 23:07 UTC

Utili

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb 2026, 23:01 UTC

Utili

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb 2026, 22:59 UTC

Utili

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 feb 2026, 22:42 UTC

Utili

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 feb 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 feb 2026, 23:46 UTC

Discorsi di Mercato

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 feb 2026, 23:36 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 feb 2026, 23:30 UTC

Discorsi di Mercato

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 feb 2026, 23:20 UTC

Discorsi di Mercato

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 feb 2026, 23:20 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

24 feb 2026, 23:16 UTC

Utili

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 feb 2026, 23:13 UTC

Utili

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 feb 2026, 23:12 UTC

Utili

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 feb 2026, 23:10 UTC

Utili

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 feb 2026, 23:10 UTC

Utili

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 feb 2026, 23:08 UTC

Utili

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 feb 2026, 23:07 UTC

Utili

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 feb 2026, 22:52 UTC

Utili

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb 2026, 22:46 UTC

Utili

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Warner Receives New Bid From Paramount -- 3rd Update

24 feb 2026, 22:29 UTC

Utili

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 feb 2026, 22:28 UTC

Utili

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 feb 2026, 22:27 UTC

Utili

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 feb 2026, 22:27 UTC

Utili

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 feb 2026, 22:25 UTC

Utili

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 feb 2026, 22:24 UTC

Utili

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 feb 2026, 22:23 UTC

Utili

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 feb 2026, 22:22 UTC

Utili

Woolworths Interim Dividend 45 Australian Cents/Share

24 feb 2026, 22:22 UTC

Utili

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 feb 2026, 22:21 UTC

Utili

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Confronto tra pari

Modifica del prezzo

Twist Bioscience Corp Previsione

Obiettivo di Prezzo

By TipRanks

8.13% in crescita

Previsioni per 12 mesi

Media 52 USD  8.13%

Alto 58 USD

Basso 50 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Twist Bioscience Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

6

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

31.56 / 38.6884Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

161 / 351 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat